Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEISMiC: Istaroxime in Pre-Cardiogenic Shock
NCT04325035Phase 2Completed
- Sponsor
- Windtree Therapeutics, Inc.
- Start
- Sep 2020
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of istaroxime in cardiogenic shock, sponsored by Windtree Therapeutics, Inc.. Started Sep 2020; status: completed.
02
Drugs
istaroxime
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on NCT04325035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04325035.